B-Phage
À propos de votre organisation / profil
B-Phage is a biotech startup dedicated to combating the antimicrobial resistance (AMR) crisis, by isolating bacteriophages and leveraging AI technology, to ultimately develop innovative therapeutics.
The problem: AMR could cause 10 million deaths annually and cost $100 trillion by 2050.
Our solution: Bacteriophage therapy.
B-Phage R&D: A phage-host biorepository, supported by a computational platform to predict phage-host interactions, leveraged to develop phage therapeutics.
Market opportunity: The AMR therapeutics market, valued at >$8 billion.
Pipeline: Preclinical testing --> phase I – III clinical trials --> phage therapeutic product to market.
Capital requirements: $ 2 million, for preclinical testing of E. coli phages to treat urinary tract infections (UTIs).
Réseau (0)
Il n'y a pas encore d'organisations dans le réseau.
Activités récentes
B-Phage a mis à jour sa levée de fonds.
B-Phage a publié une levée de fonds.
Naadira Vanker a rejoint B-Phage.